Vitamin D deficiency is associated with prostate tumor gene expression
“I think the one thing that we're hopeful for is that people will start to look at vitamin D as a potential chemoprevention agent,” says Adam B. Murphy, MD, MBA, MSCI.
In this video, Adam B. Murphy, MD, MBA, MSCI, discusses the key findings from the study, “Vitamin D has a stronger impact on prostate tumor gene expression in Black men,” which he presented at the 2022 American Urological Association annual meeting in New Orleans, Louisiana. Murphy is an assistant professor of urology and preventive medicine (cancer epidemiology and prevention) at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
